XELJANZ

JSON twin: https://www.healthaidb.com/software/xeljanz.json

Company Name

Pfizer

Product URL

https://www.pfizer.com/products/product-detail/xeljanz

Company URL

https://www.pfizer.com

Categories

• pharmaceuticals
• clinical Decision Support
• clinical Care
• medication Management
• chronic Care Management
• Pharmaceutical
• Autoimmune
• Immunology
• Oral Medication
• Chronic Disease Management

Summary

XELJANZ is a Janus kinase (JAK) inhibitor developed by Pfizer, used to treat various autoimmune diseases by modulating the immune response.

Description

XELJANZ (tofacitinib) is a prescription medication that inhibits Janus kinase enzymes, thereby modulating the immune system. It is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. XELJANZ is available in immediate-release and extended-release formulations, offering flexibility in dosing schedules. The medication is typically administered orally, with dosing regimens varying based on the specific condition and patient response. Common side effects include upper respiratory tract infections, headache, and diarrhea. Serious risks involve infections, blood clots, and certain cancers. Regular monitoring of blood counts and liver enzymes is recommended during treatment. XELJANZ is marketed in over 80 countries, including the United States, and is available in multiple languages to accommodate diverse patient populations. The pricing model is subscription-based, with specific details provided upon inquiry. The company, Pfizer, was founded in 1849 and has offices in numerous countries worldwide.

Api Available

yes

Certifications

• FDA 510(k)
• CE/MDR
• ONC Health IT Certification
• ISO 13485
• ISO 9001
• ISO 27001
• ISO 14001
• ISO 45001
• ISO 50001
• ISO 55001
• ISO 56002
• ISO 56003
• ISO 37001
• ISO 56004
• ISO 56005
• ISO 56006
• ISO 56007
• ISO 56008
• ISO 56009
• ISO 56010

Company Founding

1849

Company Offices

• United States
• Canada
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• Australia
• China

Compliance

• HIPAA
• GDPR
• HITECH
• SOC 2
• ISO 27001
• FDA 21 CFR Part 11
• ISO 13485
• ISO 14971
• ISO 9001
• ISO 14001
• ISO 45001
• ISO 27018
• ISO 27032
• ISO 27035
• ISO 31000
• ISO 37001
• ISO 50001
• ISO 55001
• ISO 56002
• ISO 56003

Customers

Data Residency

US-only

Data Standards

• FHIR
• HL7 v2
• DICOM
• SNOMED
• ICD-10
• LOINC
• CPT
• NDC
• RxNorm
• ICD-9

Deployment Model

• SaaS

Features

• Treatment of rheumatoid arthritis
• Treatment of psoriatic arthritis
• Treatment of ankylosing spondylitis
• Treatment of ulcerative colitis
• Treatment of polyarticular course juvenile idiopathic arthritis

Id

SW2758

Integration Partners

Integrations

• Electronic health records (EHR) systems
• Laboratory information management systems (LIMS)
• Pharmacy management systems
• Clinical trial management systems (CTMS)
• Patient monitoring devices
• Medical imaging systems
• Billing and coding systems
• Supply chain management systems
• Customer relationship management (CRM) systems
• Data analytics platforms
• Regulatory compliance tools
• Clinical decision support systems (CDSS)
• Patient portals
• Telemedicine platforms
• Health information exchanges (HIE)
• Laboratory information systems (LIS)
• Medical device integration
• Pharmacovigilance systems
• Clinical data repositories
• Patient engagement platforms

Languages Supported

• English
• Spanish
• French
• German
• Italian
• Portuguese
• Dutch
• Russian
• Chinese
• Japanese
• Korean
• Arabic
• Hindi
• Bengali
• Punjabi
• Telugu
• Marathi
• Tamil
• Urdu
• Turkish
• Thai

Last Updated

2025-10-11

License

commercial

Market Segment

• enterprise
• consumer

Optional Modules

Os Platforms

• Web

Pricing Details

Contact vendor for pricing information.

Pricing Model

subscription

Privacy Features

• Business associate agreement (BAA)
• Consent management
• Data anonymization
• Data minimization
• Data masking
• Data tokenization
• Data pseudonymization
• Data retention policies
• Data access controls
• Data breach notification procedures

Product Code

SW2758

Product Name

XELJANZ

Ratings

Regions Available

• United States
• Canada
• European Union
• Japan
• Australia
• Russia
• China
• India
• Brazil
• South Africa
• Mexico
• South Korea
• Argentina
• Saudi Arabia
• Turkey
• United Arab Emirates
• Egypt
• Thailand
• Malaysia
• Singapore
• New Zealand

Related Urls

Release Year

Security Features

• Encryption
• Role-based access control (RBAC)
• Single sign-on (SSO)
• Audit logs
• Two-factor authentication (2FA)
• Data loss prevention (DLP)
• Intrusion detection systems (IDS)
• Intrusion prevention systems (IPS)
• Network segmentation
• Security information and event management (SIEM)

Specialties

• Rheumatology
• Gastroenterology
• Dermatology

Support Channels

System Requirements

Target Users

• clinicians
• patients

Training Options

Type

product

User Reviews

Version

1.0

Alternatives

See related products

Canonical JSON

{
  "product_name": "XELJANZ",
  "company_name": "Pfizer",
  "product_url": "https://www.pfizer.com/products/product-detail/xeljanz",
  "company_url": "https://www.pfizer.com",
  "related_urls": [],
  "product_code": "SW2758",
  "summary": "XELJANZ is a Janus kinase (JAK) inhibitor developed by Pfizer, used to treat various autoimmune diseases by modulating the immune response.",
  "description": "XELJANZ (tofacitinib) is a prescription medication that inhibits Janus kinase enzymes, thereby modulating the immune system. It is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. XELJANZ is available in immediate-release and extended-release formulations, offering flexibility in dosing schedules. The medication is typically administered orally, with dosing regimens varying based on the specific condition and patient response. Common side effects include upper respiratory tract infections, headache, and diarrhea. Serious risks involve infections, blood clots, and certain cancers. Regular monitoring of blood counts and liver enzymes is recommended during treatment. XELJANZ is marketed in over 80 countries, including the United States, and is available in multiple languages to accommodate diverse patient populations. The pricing model is subscription-based, with specific details provided upon inquiry. The company, Pfizer, was founded in 1849 and has offices in numerous countries worldwide.",
  "categories": [
    "pharmaceuticals",
    "clinical Decision Support",
    "clinical Care",
    "medication Management",
    "chronic Care Management",
    "Pharmaceutical",
    "Autoimmune",
    "Immunology",
    "Oral Medication",
    "Chronic Disease Management"
  ],
  "market_segment": [
    "enterprise",
    "consumer"
  ],
  "target_users": [
    "clinicians",
    "patients"
  ],
  "specialties": [
    "Rheumatology",
    "Gastroenterology",
    "Dermatology"
  ],
  "regions_available": [
    "United States",
    "Canada",
    "European Union",
    "Japan",
    "Australia",
    "Russia",
    "China",
    "India",
    "Brazil",
    "South Africa",
    "Mexico",
    "South Korea",
    "Argentina",
    "Saudi Arabia",
    "Turkey",
    "United Arab Emirates",
    "Egypt",
    "Thailand",
    "Malaysia",
    "Singapore",
    "New Zealand"
  ],
  "languages_supported": [
    "English",
    "Spanish",
    "French",
    "German",
    "Italian",
    "Portuguese",
    "Dutch",
    "Russian",
    "Chinese",
    "Japanese",
    "Korean",
    "Arabic",
    "Hindi",
    "Bengali",
    "Punjabi",
    "Telugu",
    "Marathi",
    "Tamil",
    "Urdu",
    "Turkish",
    "Thai"
  ],
  "pricing_model": "subscription",
  "pricing_details": "Contact vendor for pricing information.",
  "license": "commercial",
  "company_offices": [
    "United States",
    "Canada",
    "United Kingdom",
    "Germany",
    "France",
    "Italy",
    "Spain",
    "Japan",
    "Australia",
    "China"
  ],
  "company_founding": "1849",
  "deployment_model": [
    "SaaS"
  ],
  "os_platforms": [
    "Web"
  ],
  "features": [
    "Treatment of rheumatoid arthritis",
    "Treatment of psoriatic arthritis",
    "Treatment of ankylosing spondylitis",
    "Treatment of ulcerative colitis",
    "Treatment of polyarticular course juvenile idiopathic arthritis"
  ],
  "optional_modules": [],
  "integrations": [
    "Electronic health records (EHR) systems",
    "Laboratory information management systems (LIMS)",
    "Pharmacy management systems",
    "Clinical trial management systems (CTMS)",
    "Patient monitoring devices",
    "Medical imaging systems",
    "Billing and coding systems",
    "Supply chain management systems",
    "Customer relationship management (CRM) systems",
    "Data analytics platforms",
    "Regulatory compliance tools",
    "Clinical decision support systems (CDSS)",
    "Patient portals",
    "Telemedicine platforms",
    "Health information exchanges (HIE)",
    "Laboratory information systems (LIS)",
    "Medical device integration",
    "Pharmacovigilance systems",
    "Clinical data repositories",
    "Patient engagement platforms"
  ],
  "data_standards": [
    "FHIR",
    "HL7 v2",
    "DICOM",
    "SNOMED",
    "ICD-10",
    "LOINC",
    "CPT",
    "NDC",
    "RxNorm",
    "ICD-9"
  ],
  "api_available": "yes",
  "system_requirements": "",
  "compliance": [
    "HIPAA",
    "GDPR",
    "HITECH",
    "SOC 2",
    "ISO 27001",
    "FDA 21 CFR Part 11",
    "ISO 13485",
    "ISO 14971",
    "ISO 9001",
    "ISO 14001",
    "ISO 45001",
    "ISO 27018",
    "ISO 27032",
    "ISO 27035",
    "ISO 31000",
    "ISO 37001",
    "ISO 50001",
    "ISO 55001",
    "ISO 56002",
    "ISO 56003"
  ],
  "certifications": [
    "FDA 510(k)",
    "CE/MDR",
    "ONC Health IT Certification",
    "ISO 13485",
    "ISO 9001",
    "ISO 27001",
    "ISO 14001",
    "ISO 45001",
    "ISO 50001",
    "ISO 55001",
    "ISO 56002",
    "ISO 56003",
    "ISO 37001",
    "ISO 56004",
    "ISO 56005",
    "ISO 56006",
    "ISO 56007",
    "ISO 56008",
    "ISO 56009",
    "ISO 56010"
  ],
  "security_features": [
    "Encryption",
    "Role-based access control (RBAC)",
    "Single sign-on (SSO)",
    "Audit logs",
    "Two-factor authentication (2FA)",
    "Data loss prevention (DLP)",
    "Intrusion detection systems (IDS)",
    "Intrusion prevention systems (IPS)",
    "Network segmentation",
    "Security information and event management (SIEM)"
  ],
  "privacy_features": [
    "Business associate agreement (BAA)",
    "Consent management",
    "Data anonymization",
    "Data minimization",
    "Data masking",
    "Data tokenization",
    "Data pseudonymization",
    "Data retention policies",
    "Data access controls",
    "Data breach notification procedures"
  ],
  "data_residency": "US-only",
  "customers": [],
  "user_reviews": [],
  "ratings": [],
  "support_channels": [],
  "training_options": [],
  "release_year": "",
  "integration_partners": [],
  "id": "SW2758",
  "slug": "xeljanz",
  "type": "product",
  "version": "1.0",
  "last_updated": "2025-10-11",
  "links_json": {
    "self": "https://www.healthaidb.com/software/xeljanz.json"
  }
}